Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
|Poll|January 26, 2021
Professional Opinion: Cannabis
Author(s)Psychiatric Times Editors
What are your feelings about the utility of cannabis in psychiatric practice?
Advertisement
Do you believe cannabis can be a useful tool in addressing psychiatric disorders?
Advertisement
Related to this article
National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
4
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5